TiGenix to receive €5m loan for Phase III Crohn's trial
This article was originally published in Clinica
Executive Summary
TiGenix' wholly-owned subsidiary, Cellerix, is to receive €4.95m ($6.5m) to finance a Phase III fistula programme in Crohn's disease. The funding is in the form of a soft loan from the Madrid Network, a non-profit organisation that aims to promote innovation and high value job creation in Spain’s Madrid region.